You may like
The severity of HER2-MBC
HER2-MBC is usually more aggressive and has a poorer prognosis. Although there are individual differences, the overall trend shows that patients with HER2-type are not as good as other subtypes in terms of survival and treatment response. Finding the right treatment for HER2-MBC and regular monitoring are crucial to improving prognosis.
1. Aggressiveness
Metastasis rate: About 20%-30% of HER2-breast cancer patients may already have metastatic disease at the time of initial diagnosis, compared with a lower metastasis rate for HER2+ breast cancer.
Growth rate: Some studies have shown that the Ki-67 index of the HER2-subtype is often higher than 20%, indicating that the proliferation activity of tumor cells is stronger. A high Ki-67 index is usually associated with a poorer prognosis, meaning that the tumor may be more aggressive and have an increased risk of metastasis.
2. Prognosis
Survival: According to some large-scale studies, the median survival of HER2-MBC patients is about 18-24 months, while the median survival of HER2+ MBC patients can reach more than 36 months. In some studies, the 5-year survival rate of HER2-MBC patients is about 20%-30%, while that of HER2+ patients is about 50%-60%.
3. Treatment response
Effect of chemotherapy: Studies have shown that the response rate of HER2-breast cancer patients to chemotherapy is about 30%-50%, while the response rate of HER2+ patients is higher, reaching 70%-90%.
Endocrine therapy: Although traditional endocrine therapy (such as tamoxifen and aromatase inhibitors) is effective in many HR+ and Her2-MBC patients, some patients will develop drug resistance during treatment. The progression-free survival (PFS) of HER2-MBC patients is usually short, about 1-2 years.
| Elements | meaning | HER2-（MBC） | HER2+（MBC） |
|---|---|---|---|
| Transfer rate | Probability of metastatic disease | 20%-30% | 15%-25% |
| Ki-67 | Proliferative activity of tumor cells | ＞20% | 20%-50% |
| Median survival | The median survival time of patients | 18-24（month） | 36（month） |
| 5-year survival rate | Treatment Effects | 20%-30% | 50%-60% |
| response rate | Chemotherapy effect | 30%-50% | 70%-90% |
| PFS | Progression-free survival | 1-2（year） | 12（month）+ |
HER2-MBC has a poor prognosis, especially in the absence of effective targeted therapy. With the deepening of our understanding of cancer biology, Elacestrant, as a selective estrogen receptor modulator (SERM), can specifically target estrogen receptors, especially for Her2-MBC patients. Provide a new treatment mechanism.
Elacestrant（Orserdu）Her2- MBC Treatments
1. Targeted therapy: Elacestrant is a selective estrogen receptor modulator (SERM) whose mechanism specifically targets estrogen receptors and can more effectively inhibit estrogen stimulation of breast cancer cells.
- Clinical trial results show that Elacestrant prolongs progression-free survival (PFS) in HER2- MBC patients. According to research data published in the New England Journal of Medicine in 2022, Elacestrant achieved a PFS of about 6.9 months when compared with standard treatment, compared with 4.2 months in the control group.
2. Drug resistance: Studies have shown that Elacestrant can still be effective in some patients who are resistant to other endocrine therapies, providing a new treatment option. Clinical data show that Elacestrant (Orserdu) has a response rate of about 30% for some resistant patients.
3. High safety: Orserdu is approved by European medical agencies and the U.S. Food and Drug Administration (FDA), similar to traditional endocrine therapy, with milder side effects. Clinical trials have shown that most patients tolerate it well, common side effects include mild nausea and fatigue, and the incidence of serious side effects is extremely low.
4. Oral administration: Elacestrant (Orserdu) is an oral drug, which is easy to use. Compared with injectable drugs, oral drugs are more easily accepted by patients, which helps to increase patient compliance in actual treatment.
Elacestrant (Orserdu) cost and precautions
The market price of Elacestrant (Orserdu) varies by region, drug supplier, and insurance coverage. In some countries, health insurance may cover part or all of the cost of Elacestrant, depending on the insurance plan and the patient's medical needs.
1.Insurance plan
- Most commercial health insurance plans and some cancer-specific insurance plans may provide more comprehensive drug coverage, but the specific situation depends on the drug's indications and insurance policies.
- In the United States, Medicare and state Medicaid plans may reimburse Elacestrant (Orserdu) according to local drug coverage policies, especially for eligible elderly patients. Specific reimbursement conditions need to be consulted in local policies
2.Precautions
- Elacestrant (Orserdu) is suitable for HR+ and HER2-MBC, and the patient's pathological type must be confirmed before use.
- Common side effects of Elacestrant (Orserdu) include nausea, fatigue, diarrhea, and loss of appetite. Patients need to monitor side effects regularly and communicate with their doctors to adjust treatment plans.
- When using Elacestrant, patients need to inform their doctors of other medications they are taking to avoid potential drug interactions.
- Patients with impaired liver function or other significant health problems should use with caution.
In conclusion
The complexity of Her2-MBC is a major medical challenge, but by exploring innovative treatment approaches, personalized treatment plans and effective pain management strategies, Elacestrant (Orserdu) will more effectively protect the breast health of Her2-MBC patients.